Abstract：
UNASSIGNED: Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has dramatically expanded in hematologic malignancies. Many have recently received Food Drug Administration and European Medicines Agency approvals in various stages of treatment for lymphomas, leukemias, and multiple myeloma.
UNASSIGNED: The purpose of this review is to provide an overview of bispecific antibody treatment including the mechanisms leading to effector T cells targeting tumor-associated antigens, the treatment indications, efficacies, toxicities, and challenges of the different constructs. A literature search was performed through access to PubMed and clinicaltrials.gov.
UNASSIGNED: While there has been substantial success in the treatment of NHL, MM, and ALL, there are still hematologic malignancies such as AML where there has been limited progress. It is important to continue to investigate new designs, tumor antigen targets, and further refine where current approved bispecific antibodies fit in terms of sequencing of therapy. Hopefully, with the knowledge gained in recent years and the explosion of these therapies, patients with blood cancers will continue to benefit from these treatments for years to come.
UNASSIGNED: The purpose of this review is to provide an overview of bispecific antibody treatment including the mechanisms leading to effector T cells targeting tumor-associated antigens, the treatment indications, efficacies, toxicities, and challenges of the different constructs. A literature search was performed through access to PubMed and clinicaltrials.gov.
UNASSIGNED: While there has been substantial success in the treatment of NHL, MM, and ALL, there are still hematologic malignancies such as AML where there has been limited progress. It is important to continue to investigate new designs, tumor antigen targets, and further refine where current approved bispecific antibodies fit in terms of sequencing of therapy. Hopefully, with the knowledge gained in recent years and the explosion of these therapies, patients with blood cancers will continue to benefit from these treatments for years to come.
摘要：
■自2017年双特异性抗体blinatumomab批准用于治疗复发的急性淋巴细胞白血病以来，许多双特异性抗体构建体的开发在血液系统恶性肿瘤中已显著扩展.许多人最近在淋巴瘤的不同治疗阶段获得了食品药品监督管理局和欧洲药品管理局的批准，白血病,和多发性骨髓瘤.
■这篇综述的目的是提供双特异性抗体治疗的概述，包括导致效应T细胞靶向肿瘤相关抗原的机制，治疗适应症，功效,毒性,以及不同结构的挑战。通过访问PubMed和clinicaltrials.gov进行了文献检索。
■虽然NHL的治疗取得了实质性的成功，MM,和所有,仍然存在进展有限的血液系统恶性肿瘤,如AML.重要的是要继续研究新的设计，肿瘤抗原靶标，并进一步完善目前批准的双特异性抗体在治疗测序方面的适合之处。希望,随着近年来获得的知识和这些疗法的爆炸式增长，血癌患者在未来几年将继续受益于这些治疗。
■这篇综述的目的是提供双特异性抗体治疗的概述，包括导致效应T细胞靶向肿瘤相关抗原的机制，治疗适应症，功效,毒性,以及不同结构的挑战。通过访问PubMed和clinicaltrials.gov进行了文献检索。
■虽然NHL的治疗取得了实质性的成功，MM,和所有,仍然存在进展有限的血液系统恶性肿瘤,如AML.重要的是要继续研究新的设计，肿瘤抗原靶标，并进一步完善目前批准的双特异性抗体在治疗测序方面的适合之处。希望,随着近年来获得的知识和这些疗法的爆炸式增长，血癌患者在未来几年将继续受益于这些治疗。
